Anixa Biosciences Inc. Common Stock (ANIX)
Stock · NASDAQ · Health Care
$2.67as of 10/16/2026
Price chart
Active signals
ANIX Signal Track Record
How signals performed across all stocks →What ANIX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | +4.1% | 58% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 25 | -1.5% | 40% | October 6, 2026 |
| Bollinger Band Breakout | 24 | -0.5% | 46% | October 6, 2026 |
| Bollinger Band Breakdown | 19 | +5.9% | 58% | May 18, 2026 |
| Any 20-session window (baseline) | -1.6% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 4
- Website
- www.anixa.com/
Fundamentals
- 1-day range
- $2.65$2.82
- Market cap
- $116.70M
- P/E (trailing)
- —
- P/E (forward)
- -8.61
- EPS (trailing)
- $-0.31
- Dividend yield
- —
- Beta
- 0.47
- Avg. volume
- 299.2K
How Anixa Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2023 annual results
Source: 10-K filed Jan 16, 2024 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Anixa Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ANIXAnixa Biosciences Inc. Common Stock$2.67▼ 3.96%Market cap $116.70MP/E —$2.32$5.46
- YARWYarrow Bioscience Inc. Common Stock$18.31▼ 8.45%Market cap $116.71MP/E —$18.16$44.28
- CPIXCumberland Pharmaceuticals Inc. Common Stock$7.18▼ 4.77%Market cap $115.07MP/E —$1.85$9.28
- BGMBGM Group Ltd. Class A Ordinary Shares$8.65▲ 0.70%Market cap $118.62MP/E —$6.45$303
- PMNProMIS Neurosciences Inc. Common Shares (ON)$8.15▼ 6.32%Market cap $119.54MP/E —$6.27$27.4
- CUECue Biopharma Inc. Common Stock$16.71▼ 10.50%Market cap $113.45MP/E —$4.97$45.5
- GNLXGenelux Corporation Common Stock$2.42▼ 2.42%Market cap $121.07MP/E —$2.29$8.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ANIX Anixa Biosciences Inc. Common Stock | $116.70M | — | $2.67 | ▼ 3.96% | $2.32$5.46 |
| YARW Yarrow Bioscience Inc. Common Stock | $116.71M | — | $18.31 | ▼ 8.45% | $18.16$44.28 |
| CPIX Cumberland Pharmaceuticals Inc. Common Stock | $115.07M | — | $7.18 | ▼ 4.77% | $1.85$9.28 |
| BGM BGM Group Ltd. Class A Ordinary Shares | $118.62M | — | $8.65 | ▲ 0.70% | $6.45$303 |
| PMN ProMIS Neurosciences Inc. Common Shares (ON) | $119.54M | — | $8.15 | ▼ 6.32% | $6.27$27.4 |
| CUE Cue Biopharma Inc. Common Stock | $113.45M | — | $16.71 | ▼ 10.50% | $4.97$45.5 |
| GNLX Genelux Corporation Common Stock | $121.07M | — | $2.42 | ▼ 2.42% | $2.29$8.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical TrialYahoo · 10/5/2026
- Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose CohortBenzinga · 10/5/2026
- Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical TrialYahoo · 10/1/2026
- Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian CancerBenzinga · 10/1/2026
- HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Lowers Price Target to $6Benzinga · 9/22/2026
- Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040Yahoo · 9/21/2026
- IP Australia Grants Patent To Anixa Biosciences’ Breast Cancer Vaccine Technology, Exclusively Licensed From Cleveland ClinicBenzinga · 9/21/2026
- Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory BoardYahoo · 9/16/2026
Insider Activity
Insider Actions →- Arnold M. Baskies · September 24, 2026 · Buy5.0K @ $2.76
- Amit Kumar · September 24, 2026 · Buy7.0K @ $2.78
- Lewis H. Titterton Jr. · September 23, 2026 · Buy49.0K @ $2.69
- Amit Kumar · September 10, 2026 · Buy3.0K @ $2.75
- Amit Kumar · September 10, 2026 · Buy5.0K @ $2.76
- Lewis H. Titterton Jr. · September 10, 2026 · Buy10.0K @ $2.73
- Amit Kumar · July 31, 2026 · Buy5.0K @ $3.47
- Amit Kumar · July 27, 2026 · Buy5.0K @ $3.44
- Arnold M. Baskies · July 27, 2026 · Option Exercise6.0K @ $3.13
- Arnold M. Baskies · July 27, 2026 · Tax Withholding5.4K @ $3.46
- Amit Kumar · July 27, 2026 · Buy3.2K @ $3.37
- Amit Kumar · July 24, 2026 · Buy3.0K @ $3.73
- Amit Kumar · July 20, 2026 · Buy5.0K @ $3.46
- Lewis H. Titterton Jr. · July 20, 2026 · Buy12.0K @ $3.47
- Lewis H. Titterton Jr. · July 15, 2026 · Buy2.8K @ $3.28
Institutional Ownership
March 31, 2026
- Total shares held
- 4.96M
- Total value held
- $12.50M
- Institutional holders
- 59
- Unknown1.31M
- Unknown566.3K
- Unknown551.6K
- Unknown539.3K
- Unknown364.7K
- Unknown173.2K
- Unknown170.1K
- Unknown159.0K
- Unknown133.7K
- Unknown98.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Anixa Biosciences Secures First Australian Patent for Breast Cancer Vaccine
Anixa Biosciences received its first Australian patent for its breast cancer vaccine technology, extending global protection through 2040. This milestone strengthens the company's intellectual property position for a product exclusively licensed from the Cleveland Clinic. While HC Wainwright & Co. recently lowered its price target to $6, the patent grant provides a concrete regulatory and legal development for the stock.
Anixa Biosciences Secures First Australian Patent for Breast Cancer Vaccine. Anixa Biosciences received its first Australian patent for its breast cancer vaccine technology, extending global protection through 2040. This milestone strengthens the company's intellectual property position for a product exclusively licensed from the Cleveland Clinic. While HC Wainwright & Co. recently lowered its price target to $6, the patent grant provides a concrete regulatory and legal development for the stock.